N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=188 Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
N/A N=349 Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
N/A N=47 FAST (Fluid Accumulation Status Trial)
Congestive Heart Failure · Cardiomyopathy · Dyspnea
Primary: Number of Subjects With at Least 30 Days of Daily Impedance Measurements — 47; 106 participants
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 3 N=110 A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Edema, Cardiac
Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001
N/A N=513 The Darlington Retrospective Outpatient Study
Heart Failure
Primary: All Cause Mortality — 163; 118 participants
N/A N=41 Curing Atrial Fibrillation in Heart Failure
Chronic Heart Failure · Atrial Fibrillation
Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat
Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Phase 3 N=20 A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Cardiac Edema
Primary: Body Weight — -1.68; -2.14 Kg
N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
Phase 3 N=121 Heart Rate Reduction in Heart Failure
Heart Failure
Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters
N/A N=677 Unexpected Cardiac Arrest in Intensive Care Unit
Heart Arrest
Primary: Number of Patients With Unexpected Cardiac Arrest — 677; 30,722 Participants
N/A N=11 Exercise Training in Heart Failure: Changes in Cardiac Structure and Function
Heart Failure
Primary: Change in Left Ventricular Systolic Function. — .82; -1.90 percent LVEF — p=.14
Phase 4 N=16 Effect of Aldosterone on Energy Starvation in Heart Failure
Heart Failure · Nonischemic Dilated Cardiomyopathy
Primary: Left Ventricular Work-metabolic Index (WMI) at Baseline — 7.4 (x10^6), mL x mm Hg/m^2
N/A N=71 Myocardial Lipid and Creatine of Heart Failure on MRS
Myocardial Lipid
Primary: Myocaridal Lipid on MRS — 1.72; 1.18; 1.53; 0.93 ratios
N/A N=150 Palliative Care in Heart Failure
Heart Failure · Heart Diseases · Cardiovascular Diseases
Primary: Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) — 36.1; 31.4; 63.1; 52.1 units on a scale — p=0.1641
Phase 2 N=45 A Study of CK-1827452 Infusion in Stable Heart Failure
Heart Failure
Primary: Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations — 84; 62; 42; 24 msec — p=0.8842
N/A N=47 Synchronized Cardiac Assist for Cardiogenic Shock
Shock, Cardiogenic · High Risk Percutaneous Coronary Interventions
Primary: Number of Participants With Device and Procedure Related Serious Adverse Events — 11; 5 Participants
Phase 2 N=130 Thiamine and Acute Decompensated Heart Failure: Pilot Study
Heart Failure · Diabetes
Primary: Effect of Thiamine Supplementation on Dyspnea — 34; 32 mm
Phase 2 N=182 Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
N/A N=13 Effect of Chronic Changes in Heart Rate on Congestive Heart Failure
Heart Failure, Congestive
Primary: Ejection Fraction — 33; 30; 25 % of blood ejected with each beat
Phase 2 N=65 The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
Stem Cell Transplantation · Ventricular Dysfunction, Left
Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…
N/A N=602 Heart Failure Optimization Study
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
N/A N=194 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Survival — 112; 6; 18; 19 participants
Phase 4 N=36 Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)
Heart Failure · CHF
Primary: Time Required for the Pulmonary Artery Occlusion Pressure (PAOP) to be Maintained at a Value of Less Than or Equal to 18 mmHg for at Least Four Consecutive Hours (+/- 30…
Phase 4 N=300 Clinical Study of Lipoic Acid on Ischemic Heart Failure
Ischemic Heart Failure
Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants
Phase 2 N=66 Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure
Heart Failure
Primary: Evaluate the Reduction in Left-ventricular End Systolic Volume Index (LVESVi) After 6 Months of Spinal Cord Stimulation (SCS) Therapy in the Treatment Arm Compared to…